News releases from Varian
China Medical University Hospital Treats First Patient with Ethos™ Therapy in Taiwan, Expanding Access to Personalized Cancer Care
September 09, 2021
Varian, a Siemens Healthineers company, announced today that China Medical University Hospital in Central Taiwan treated its first patient with Ethos™ therapy, making it the first hospital in Taiwan...
Icon Group First in World to Adopt New Multi-Disciplinary Oncology Information System from Varian
August 05, 2021
Varian, a Siemens Healthineers company, announced today that cancer patients in Australia will be the first in the world to benefit from streamlined, coordinated cancer care facilitated by an upcoming...
Varian Receives FDA "Breakthrough Device Designation" for its Cardiac Radioablation (CRA) System for Treatment of Refractory Ventricular Tachycardia (VT)
May 26, 2021
- Varian's CRA system has been designated a "breakthrough device" by the FDA because of its potential to offer a more effective treatment for select patients with refractory VT.
Varian (NYSE: VAR), a Siemens Healthineers company, has signed an agreement with Australia's Icon Group to provide 30 linear accelerators and associated treatment software to help tackle the growing...
Varian Wins Best After-Sales Service Award for Radiotherapy Products in China for Fourth Consecutive Year
April 12, 2021
Varian (NYSE: VAR) today announced it received the Best After-Sales Service Award for Radiotherapy Products in the 2020 Chinese Medical Devices Industry Data and After-Sales Service Survey for the...
Company will work closely with Google Cloud and build AI tools for radiation oncology organ segmentation using the Google Cloud AI Platform
Varian Medical Systems Invests in Bend It Technologies, Ltd., a Company Developing Novel Steerable Microcatheters
March 25, 2021
Patented technology provides interventionalists with 3D-controlled bending and navigation capabilities for peripheral vascular, neurovascular and cardiology indications
Varian Announces CEO Succession Plan
March 02, 2021
CTSI Oncology Solutions, a Varian Company, to Provide Technology-Enabled Services for Radiation Oncology at CHRISTUS Health
February 24, 2021
Varian Becomes First Medical Technology Company Joining the Cancer Drug Development Forum
February 18, 2021
Varian (NYSE: VAR) announced it has joined the Cancer Drug Development Forum (CDDF) as an industry partner. This makes Varian the first medical technology company to join CDDF, the leading...
Varian Installs World's First ProBeam® 360° Proton Therapy System at Penn Medicine Lancaster General Health
February 04, 2021
Varian (NYSE: VAR) has started the installation of the cyclotron and gantry for its ProBeam® 360° single-room proton therapy system at Penn Medicine Lancaster General Health's Ann B. Barshinger Cancer...
Varian Reports Results for First Quarter of Fiscal Year 2021
January 26, 2021
Varian (NYSE: VAR) has been recognized again as the leader in the annual IMV ServiceTrak™ Radiation Oncology Systems report, ranking first in all nine of the tracked categories. Additionally, Varian's...
Varian and the Cincinnati Children's/UC Health Proton Therapy Center Announce Initial Patient Treated in the FAST-01 First Human Clinical Trial of FLASH Therapy for Cancer
November 19, 2020
Varian Medical Systems Invests in COTA, Inc. to Help Drive Faster, More Accurate Data-Driven Cancer Care
November 10, 2020
Varian (NYSE: VAR) today announced a new $10M investment and collaboration agreement with COTA, Inc., a Boston-based curator of clinical data in oncology. Both companies will work together to empower...
Varian Reports Results for Fourth Quarter of Fiscal Year 2020
October 27, 2020
Varian Congratulates Historic Trade Package Agreement with Brazil
October 20, 2020
Varian (NYSE: VAR) congratulates the United States Trade Representative and the Ministry of Development, Industry and Foreign Trade of Brazil on achieving the first steps of a trade agreement focused...
Varian Announces Presence at American Society for Radiation Oncology (ASTRO) Annual Meeting Highlighting Advancements in Intelligent Cancer Care™
October 19, 2020
Varian Stockholders Approve Combination with Siemens Healthineers
October 15, 2020
Varian (NYSE: VAR) today announced that its stockholders have voted to approve the previously announced pending combination with Siemens Healthineers AG (Frankfurt: SHL) at a special meeting. Varian...
Varian Receives Investigational Device Exemption (IDE) and Prepares for First Ever Clinical Trial of FLASH Therapy
October 12, 2020
The FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases) study is a significant milestone in the development of FLASH therapy
Varian Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China
September 16, 2020
Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire on...
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
September 15, 2020
Varian Announces Appointment of Chris Toth as President and Chief Operating Officer
September 14, 2020
Varian Announces Goshen Center for Cancer Care Treats First Patient with Ethos® Therapy, Expanding Access to Personalized Cancer Care
September 10, 2020
Adaptive therapy provides the ability to personalize patient treatment at the time of treatment based on patient's anatomy and precise position
Germany's first Ethos Therapy Ordered by the German Cancer Research Center
September 09, 2020
Varian (NYSE: VAR) today announced the German Cancer Research Center (DKFZ) in Heidelberg has ordered Germany's first Ethos™ therapy, an Adaptive Intelligence™ solution. This artificial intelligence...
Varian Reports Results for Third Quarter of Fiscal Year 2020
August 02, 2020
Cancels Upcoming Third Quarter Conference Call in Light of Pending Transaction with Siemens Healthineers
Brings Together Highly Complementary Portfolios to Empower Clinicians and Patients in the Fight Against Cancer